|

Interview with Dr. Erica Zelfand

ByPsychedelic Spotlight

Similar Posts

  • Cause of Matthew Perry’s Tragic Passing Brings to Light the Stigma Still Tied to Ketamine and Other Psychedelics Being Used to Save Lives

    Culture, Learn

    As the news surrounding Perry’s cause of death spread across social media this past weekend, so too did waves of misinformed, speculative-driven comments about ketamine and in the process bringing to light the stigma that is still very much tied to ketamine and other psychedelic drugs that are being used exclusively for therapeutic purposes.

  • BIG MindMed MDMA Trial, Atai to Compete with Elon’s Neuralink ? (+ Updates on CMPS, MYCO and ENBI)

    Listen, Videos

    Hey Psychedelic Investors! There’s been so much news this week that we decided to split “This Week In Psychedelic Stocks” in 2 parts. Part Deux: ” BIG MindMed MDMA Trial, Atai’s to Compete with Tesla’s Neuralink (+Updates on CMPS, MYCO and ENBI)” might be a lot more interesting to some of you, however, I would suggest you watch Part I entitled: “HUGE Studies Released: Psychedelics About to TAKE OVER the Stock market?” That is if you are interested in the general developments in the psychedelic industry for this week.

    In this episode, there’s lots of news for the psychedelic industry writ large. We’ll start up with three different studies that were released in the first week of April.

    1. We’ll cover some MindMed News [ MMED / MMEDF recently announced a new MDMA study ]
    2. Atai Life Sciences’ Computer Brain Interface & their clinical trial to treat Schizophrenia
    3. Compass Pathways (CMPS) has amazing new price targets
    4. Mydecine (MYCO / MYCOF ) has progressed four new compounds towards clinical trials
    5. Entheon’s (ENBI / ENTBF) new Genetic Test Kit Updates

    ​…
    ​Timestamps:
    0:00​ – Intro
    1:47 – MindMed’s (MMED / MMEDF / MMQ) Announcing New Data on Personalized MDMA Dosing
    6:08 – Atai Life Sciences acquires Psyber Inc to develop Brain Computer Interface -enabled digital therapeutics targeting mental health disorder
    8:00 – Atai’s Subsidiary, Recognify Life Sciences, to Commence Phase 2 clinical study in Cognitive Impairment associated with Schizophrenia
    9:07 – Roth Capital Upgrades Compass Pathways (CMPS) price targets & CMPS has scheduled a corporate update
    10:32 – Mydecine ( MYCOF / MYCO ) Announces Four New Lead Drug Candidates for Pre-IND Meetings with the FDA & Health Canada to prepare for clinical trials. ( MYCO 001, MYCO 002, MYCO 003 & MYCO 004 )
    13:02 – Entheon Biomedical (ENBI / ENTBF ) has now launched Halugen’s Psychedelics’ Genetic KIT
    So that’s it for This Week in Psychedelic Stocks fellow psychedelic investors!

    I hope you guys found some value in this! As our thumbnail titles states: The SHROOM BOOM is REAL! Psychedelics are taking the world by storm and psychedelic inspired companies are releasing news every single day. We’ll try to cover most of them but if there’s a company you want us to cover more in debt, please let us know in the comments and we’ll try to satisfy your demands.

    Remember to Like, Subscribe, and SMASH that notifications bell to keep up to date on all the latest Psychedelic Stocks news!

    Follow us on social media! 🙌
    Instagram: @psychedelicinvestor
    Facebook: @thepsychedelicinvestor

    If you want to collaborate shoot us an email at: thepsychedelicinvestor@gmail.com

    Music: www.bensound.com
    https://benzinga.grsm.io/jameshallifa
    ​…
    ​
    https://benzinga.grsm.io/thepsychedel

    DISCLAIMER: I am not a financial adviser nor a CPA. These videos are for educational and entertainment purposes only. Investing of any kind involves risk. While it is possible to minimize risk, your investments are solely your responsibility. It is imperative that you conduct your own research. I am merely sharing my opinion with no guarantee of gains or losses on investments.

    #MindMed​​​​ ​#MMEDStock #CMPS Stock